EGFR and metastatic colorectal cancer: Circ-EGFR was identified as a novel predictive biomarker for cetuximab efficacy in KRAS wild-type metastatic colorectal cancer, which was successfully translated into a non-invasive liquid biopsy assay for predicting responses to anti-EGFR therapy.